Breaking News
Get 50% Off 0
📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-Earnings Read more

LAVA Therapeutics NV (LVTX)

Create Alert
Create Alert
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile






Follow LAVA Therapeutics NV's earnings

Delivery Method


Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
1.800 -0.080    -4.26%
15/07 - Closed. Currency in USD ( Disclaimer )
After Hours
17:46:13 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 121,117
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.720 - 1.910
LAVA Therapeutics NV 1.800 -0.080 -4.26%

LAVA Therapeutics NV Company Profile

Get an in-depth profile of LAVA Therapeutics NV, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research


Equity Type


LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Contact Information

Address Yalelaan 62
Utrecht, 3584 CM
Phone 31 85 016 3100
Fax -

Top Executives

Name Age Since Title
Kapil Dhingra 65 2021 Non-Executive Chairman
Karen J. Wilson 61 2021 Independent Non-Executive Director
Stephen Allen Hurly 56 2019 CEO, President & Executive Director
James Julian Noble 65 2022 Independent Non-Executive Director
Andrea van Elsas 58 2018 Chairman of Advisory Board
Padmanee Sharma - 2020 Member of Advisory Board
James Patrick Allison - 2020 Member of Advisory Board
K. Dane Wittrup - - Member of Advisory Board
Madhav V. Dhodapkar - - Member of Advisory Board
Jay Thomas Backstrom 69 2022 Non-Executive Director
Dieter Kabelitz - - Member of Advisory Board
Mary E. Wadlinger 64 2023 Non-Executive Director
Christy J. Oliger 54 2023 Non-Executive Director
Peter A. Kiener 72 2023 Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your profile, will be public on and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

LVTX Comments

Write your thoughts about LAVA Therapeutics NV
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ace Geo
Ace Geo Apr 22, 2024 1:29PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Excited for the May conference call!
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email